Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT)
ARQT Stock Predictions and Ratings
WSX Rating:
STRONG BUY
WSX Forecast (1yr):
23.20%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
61.60%
ARQT Stock Analysis
ARQT
PE Ratio:
ARQT
PEG Ratio:
ARQT
Forward EPS Growth (12 month):
400.00%
ARQT
PS Ratio:
6.4
ARQT
PSG Ratio:
0.2
ARQT
Forward Revenue Growth (12 month):
29.80%
ARQT Articles
No data was found